The perceptions of pharmacists in Victoria, Australia on pharmacogenetics and its implications
Objectives: This study aimed to explore how well Victorian pharmacists perceived they understood pharmacogenetics, their perceived capacity to counsel a patient about such testing, how they believed pharmacogenetics would impact upon their profession, and to investigate the ways in which Victorian pharmacists would like to be educated about pharmacogenetics.
Methods: A cross-sectional survey was dispatched to 800 Victorian pharmacists. The participants were randomly selected and the survey was anonymous. The survey contained questions about where the pharmacists worked, the pharmacists’ perceived knowledge of pharmacogenetics, how well they believed they would be able to counsel patients about pharmacogenetic testing, how they thought pharmacists should be educated on the topic and how they believed pharmacogenetics would impact upon their profession.
Results: 291 surveys were returned (36% response rate). Results suggest that Victorian pharmacists generally perceived they had a poor understanding of pharmacogenetics and that those who have more recently graduated from tertiary education had a better perceived understanding than those who have been in the workforce for longer. Most pharmacists indicated that they did not believe that they could counsel a patient adequately about the results of a pharmacogenetic test. Regarding education about pharmacogenetics, participants suggested that this would be best delivered during tertiary studies, and as seminars and workshops forming part of their continuing professional development. Although some pharmacists were unsure how pharmacogenetics would affect their profession, many believed it would have a major impact upon their role as a pharmacist and lead to improved patient care. Some concerns about the implementation of pharmacogenetics were noted, including economic and ethical issues.
Conclusion: This study highlights the need for further research across the pharmacy profession in Australia on the issue of preparedness for the putative incorporation of pharmacogenetics into the healthcare system and everyday practice.
Keywords: Pharmacogenetics. Pharmacists. Health Knowledge, Attitudes, Practice. Australia.
2. Clemerson JP, Payne J, Bissell P, Anderson C. Pharmacogenetics, the next challenge for pharmacy? Pharm World Sci. 2006;28(3):126-130.
3. El-Ibiary SY, Cheng C, Alldredge B. Potential roles for pharmacists in pharmacogenetics. J Am Pharm Assoc. 2003;48(2):21-29.
4. Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. Int J Qual Health Care. 2003;15(Suppl.1):149-159.
5. Nelson MR, Bacanu SA, Mosteller M, Bowman CE, Roses AD, Lai EH, EHM MG. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J. 2009 9(1):23-33.
6. Shih T. Pharmacogenetics: From bench science to the bedside. Drug Inf J. 2008;42(5):503-513.
7. Anderson Jl, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KN, Muhlestein JM, Carlquist JF. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. Circulation. 2007;166(22):2563-2570.
8. Hiratsuka M, Sasaki T, Mizugaki M. Genetic testing for pharmacogenetics and its clinical application in drug therapy. Clinica Chimica Acta. 2006;363(1-2):177-186.
9. Bukaveckas B . Adding Pharmacogenetics to the Clinical Laboratory: Narrow Therapeutic Index Medications as a Place to Start. Arch Pathol Lab Med. 2004;128(12):1330.
10. Haddy CA, Ward HM, Angley MT, McKinnon RA. Consumers' views of pharmacogenetics-A qualitative study. Res Social Adm Pharm. 2010;6(3):221-231.
11. Brien JAE. Pharmacogenetics and the future of clinical pharmacy practice. Pharm J. 2008;38(1):7.
12. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics. 2004:22(8):481-493.
13. Corkindale D, Ward H, McKinnon R. Low adoption of pharmacogenetic testing: an exploration and explanation of the reasons in Australia. Per Med. 2007;4(2):191-199.
14. Evans WE, McLeod HE. Pharmacogenomics - Drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538-549.
15. Latif DA, McKay AB. Pharmacogenetics and pharmacogenomics instruction in colleges and schools of pharmacy in the United States. Am J Pharm Educ. 2005;69(2):152-156.
16. Shin J, kayser SR, Langaee TY. Pharmacogenetics: from discovery to patient care. Am J Health Syst Pharm. 2009;66:625-637.
17. Venter J. The sequence of the human genome. Science. 2001;291(5507):1304-1351.
18. Clemerson J, Payne K. Pharmacogenetics- Background and future potential. Hosp Pharm. 2008; 15(5): 159-164.
19. US Department of Health & Human Services and Stanford University. PharmGKB; Pharmacogenetics Knowledge Base [online] 2010; www.pharmgkb.org/index.jsp. (accessed 7th October 2010).
20. U.S. Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels [online] 2010; http://www.fda.gov.htm (accessed 7th October 2010).
21. National Institute of General Medical Sciences. From genes to personalised medicines [online] 2010; www.nigms.nih.gov/Initiatives/PGRN/Background/FactSheet.htm (accessed 7th October 2010).
22. Newton R. How will pharmacogenetics impact on pharmacy practice? Pharmacists' views and educational priorities. Birmingham: NHS National Genetics Education and Development Centre, 2007.
23 Guttmacher AE, Porteous ME, McInernay JD. Educating health-care professionals about genetics and genomics. Nat Rev Genet. 2007;8(2):151-157.
24. Sansgiry SS, Kulkarni AS. The human genome project: Assessing confidence in knowledge and training requirements for community pharmacists. J Manag Care Pharm 2002;8(6):525.
25. Liamputtong P. ed. Research methods in health : foundations for evidence-based practice. South Melbourne: Oxford University Press, 2010.
26. Shin J, Kayser SR. Clinical pharmacy consultation for pharmacogenetic testing. Per Med. 2009;6(2):183-192.
27. Brock TP, Valgus JM, Smith SR, Summers KM. Pharmacogenomics: implications and considerations for pharmacists. Pharmacogenomics. 2003;4(3):321-330.
The authors hereby transfer, assign, or otherwise convey to Pharmacy Practice: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print pr epublish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to Pharmacy Practice with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Author Self-Archiving Policy
Pharmacy Practice permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.